Skip to main content

Advertisement

SpringerLink
Log in

Survival Benefit of Left Lower Paratracheal (4L) Lymph Node Dissection for Patients with Left-Sided Non-small Cell Lung Cancer: Once Neglected But of Great Importance

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to compare survival outcomes between non-small cell lung cancer (NSCLC) patients with or without 4L node dissection (4LND) and to evaluate the potential patient population who will particularly benefit from 4LND.

Methods

Between January 2009 and December 2015, a total of 2063 patients with primary left-sided NSCLC in the Western China Lung Cancer Database were initially reviewed. After exclusion, 1064 patients were enrolled in this study. A total of 460 patients with 4LND (4LND+ group) were matched with 460 patients without 4LND (4LND− group) using propensity-matched analysis. Disease-free survival (DFS) and overall survival (OS) were analyzed.

Results

The metastasis rate of station 4L was 14.6%. Patients with 4LND showed higher DFS (5-year DFS 52.6% vs. 46.7%; hazard ratio [HR] 1.25, 95% confidence interval [CI] 1.03–1.50; p = 0.022) and OS (5-year OS 65.8% vs. 56.3%; HR 1.36, 95% CI 1.10–1.69; p = 0.006) than patients without 4LND. In the multivariate analysis, patients without 4LND (HR 1.33, 95% CI 1.07–1.66; p = 0.011), tumor size > 3 cm, lymph node metastasis, and pathologic stage higher than stage I were independent prognostic factors for poor OS. Subgroup analysis according to pathologic TNM stage and N stage showed that stage II, IIIA, and N2 disease indicated better survival outcomes in the 4LND+ group (p = 0.050, p = 0.016, and p = 0.008, respectively).

Conclusions

Performing 4LND may bring survival benefits to patients with left-sided NSCLC. We suggest 4LND as a standard procedure for left-sided NSCLC patients with stage II or advanced stage disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  Google Scholar 

  2. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi89–98.

    Article  Google Scholar 

  3. Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg. 1998;227(1):138-144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg. 1998;22(3):290–4 (discussion 294–5)

    Article  CAS  PubMed  Google Scholar 

  5. Keller SM, Adak S, Wagner H, Johnson DH, Eastern Cooperative Oncology Group. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Ann Thorac Surg. 2000;70(2):358–65 (discussion 356–65)

    Article  CAS  PubMed  Google Scholar 

  6. Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002;36(1):1–6.

    Article  PubMed  Google Scholar 

  7. Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80(1):268–74 (discussion 274–65)

    Article  PubMed  Google Scholar 

  8. 8. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141(3):662-670.

    Article  PubMed  PubMed Central  Google Scholar 

  9. National Comprehensive Cancer Network. NCCN guideline for non-small cell lung cancer. Version 3. NCCN; 2018.

  10. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardio-thorac Surg. 2006;30(5):787–92.

    Article  Google Scholar 

  11. Riquet M. Bronchial arteries and lymphatics of the lung. Thorac Surg Clin. 2007;17(4):619–38

    Article  PubMed  Google Scholar 

  12. Riquet M, Arame A, Foucault C, Le Pimpec BF. Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones. Interact Cardiovasc Thorac Surg. 2010;11(3):260–4.

    Article  PubMed  Google Scholar 

  13. Kuzdzal J, Zielinski M, Papla B, et al. Transcervical extended mediastinal lymphadenectomy: the new operative technique and early results in lung cancer staging. Eur J Cardio-thorac Surg. 2005;27(3):384–90 (discussion 390)

    Article  Google Scholar 

  14. Wang YN, Yao S, Wang CL, et al. Clinical significance of 4L lymph node dissection in left lung cancer. J Clin Oncol. 2018;36(29):2935–42.

    Article  PubMed  Google Scholar 

  15. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81.

    Article  PubMed  Google Scholar 

  16. Liu L, Che G, Pu Q, et al. A new concept of endoscopic lung cancer resection: Single-direction thoracoscopic lobectomy. Surg Oncol. 2010;19(2):e71–7.

    Article  PubMed  Google Scholar 

  17. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568–77.

    Article  PubMed  Google Scholar 

  18. Liu C, Pu Q, Guo C, et al. Non-grasping en bloc mediastinal lymph node dissection for video-assisted thoracoscopic lung cancer surgery. BMC surgery. 2015;15(38).

  19. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.

    Article  PubMed  Google Scholar 

  21. Kuroda H, Sakao Y, Mun M, et al. Lymph node metastases and prognosis in left upper division non-small cell lung cancers: the impact of interlobar lymph node metastasis. PLoS One. 2015;10(8):e0134674.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sun F, Zhan C, Shi M, et al. Is routine dissection of the station 9 lymph nodes really necessary for primary lung cancer? Int J Surg. 2016;34:53–7.

    Article  PubMed  Google Scholar 

  23. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60.

    Article  PubMed  Google Scholar 

  24. 24. Douillard J, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.

    Article  CAS  PubMed  Google Scholar 

  25. Pignon J, Tribodet H, Scagliotti G, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.

    Article  PubMed  Google Scholar 

  26. Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris H. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80(1):268–74 (discussion 274–65)

    Article  PubMed  Google Scholar 

  27. Coello M, Luketich J, Litle V, Godfrey T. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer. 2004;5(4):214–25.

    Article  PubMed  Google Scholar 

  28. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e211S–50S.

    Article  PubMed  Google Scholar 

  29. Leong T, Loveland P, Gorelik A, Irving L, Steinfort D. Preoperative staging by EBUS in cN0/N1 lung cancer: systematic review and meta-analysis. J Bronchology Interv Pulmonol. Epub 22 Aug 2018. https://doi.org/10.1097/lbr.0000000000000545

  30. Nagashima T. Thoracoscopic left mediastinal lymph node dissection. Ann Transl Med. 2016;4(1):10.

    PubMed  PubMed Central  Google Scholar 

  31. 31. Watanabe A, Nakazawa J, Miyajima M, et al. Thoracoscopic mediastinal lymph node dissection for lung cancer. Semin Thorac Cardiovasc Surg. 2012;24(1):68–73.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Kejia Zhao and Shiyou Wei contributed equally to this work and should be considered as co-first authors.

Authors and Affiliations

  1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China

    Kejia Zhao MD, Shiyou Wei MD, Jiandong Mei MD, PhD, Chenglin Guo MD, PhD, Yang Hai MD, Nan Chen MD & Lunxu Liu MD, PhD

  2. Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, People’s Republic of China

    Kejia Zhao MD, Shiyou Wei MD, Jiandong Mei MD, PhD, Chenglin Guo MD, PhD, Yang Hai MD, Nan Chen MD & Lunxu Liu MD, PhD

Authors
  1. Kejia Zhao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiyou Wei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiandong Mei MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chenglin Guo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Hai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nan Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lunxu Liu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lunxu Liu MD, PhD.

Ethics declarations

Disclosure

Kejia Zhao, Shiyou Wei, Jiandong Mei, Chenglin Guo, Yang Hai, Nan Chen, and Lunxu Liu have declared no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 112 kb)

Supplementary material 2 (DOCX 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, K., Wei, S., Mei, J. et al. Survival Benefit of Left Lower Paratracheal (4L) Lymph Node Dissection for Patients with Left-Sided Non-small Cell Lung Cancer: Once Neglected But of Great Importance. Ann Surg Oncol 26, 2044–2052 (2019). https://doi.org/10.1245/s10434-019-07368-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07368-x

Search

Navigation